Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 249 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Microarray Analysis Clear all
Withdrawn Phase 2Phase 3 Interventional

Functional Microarray Augmentation of Skin Treatment With Lidocaine

NCT01145326
View directory record Official record
Conditions
Pain Perception, Phlebotomy
Interventions
4% lidocaine gel application with sham microneedle device, Microneedle-facilitated lidocaine application
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 21, 2026, 5:44 PM EDT
Completed No phase listed Observational

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

NCT00900263
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma, Precancerous Condition
Interventions
cytogenetic analysis, microarray analysis, biologic sample preservation procedure, laboratory biomarker analysis
Genetic · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
69
States / cities
Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 21, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

NCT01192815
View directory record Official record
Conditions
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies, gene expression analysis, 3-dimensional conformal radiation therapy, biopsy, pharmacological study, laboratory biomarker analysis, questionnaire administration, enzyme-linked immunosorbent assay, polymorphism analysis
Drug · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 21, 2026, 5:44 PM EDT
Completed No phase listed Observational

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01190943
View directory record Official record
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00390403
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
R-(-)-gossypol acetic acid, temozolomide, gene expression analysis, mutation analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 21, 2026, 5:44 PM EDT
Terminated No phase listed Observational Results available

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

NCT00898937
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, breast biopsy
Genetic · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT01155583
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
azacitidine, lenalidomide, dexamethasone, DNA methylation analysis, gene expression analysis, bone marrow aspiration, immunohistochemistry staining method, reverse transcriptase-polymerase chain reaction, flow cytometry
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00482495
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bevacizumab, gene expression analysis, protein expression analysis, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 21, 2026, 5:44 PM EDT
Withdrawn Phase 2 Interventional

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01055301
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
21
States / cities
Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 5:44 PM EDT
Terminated Not applicable Interventional Results available

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

NCT00720096
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Liposomal Doxorubicin, Topotecan
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 21, 2026, 5:44 PM EDT
Completed No phase listed Observational

Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

NCT00899509
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
3
States / cities
Sioux City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 21, 2026, 5:44 PM EDT
Not listed No phase listed Observational

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

NCT00900224
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, DNA methylation analysis, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

NCT01231399
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, everolimus, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis
Drug · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT01149850
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Interventions
bevacizumab, temozolomide, laboratory biomarker analysis, immunohistochemistry staining method, microarray analysis, DNA methylation analysis
Biological · Drug · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:44 PM EDT
Completed No phase listed Observational

Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition

NCT00342277
View directory record Official record
Conditions
Preterm Birth, Premature Rupture of Membranes
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
6,838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 21, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

NCT00567229
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
rituximab, lenalidomide, microarray analysis, flow cytometry, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 21, 2026, 5:44 PM EDT
Withdrawn No phase listed Observational

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

NCT00897143
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
microarray analysis, mutation analysis, flow cytometry, immunologic technique
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 21, 2026, 5:44 PM EDT
Not listed No phase listed Observational

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
RNA sequencing, Transcriptome analysis, Trastuzumab, Chemotherapy
Other · Drug
Lead sponsor
OmicsWay Corp.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Timeline
2017 – 2022
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00770471
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Not applicable Interventional Results available

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
Procedure · Other · Genetic + 1 more
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 21, 2026, 5:44 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders

NCT04872452
View directory record Official record
Conditions
Small Fiber Neuropathy, Gastrointestinal Dysmotility
Interventions
Skin biopsy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 21, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

NCT01854294
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GM604, Placebo comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 21, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

NCT00363779
View directory record Official record
Conditions
Large Granular Lymphocytic Leukemia, LGL Leukemia
Interventions
Cyclosporine, Gene expression analysis, Microarray analysis, Laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 21, 2026, 5:44 PM EDT
Completed No phase listed Observational

Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524

NCT00898820
View directory record Official record
Conditions
Lung Cancer
Interventions
gene expression analysis, polymorphism analysis, protein expression analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 21, 2026, 5:44 PM EDT